Literature DB >> 34321580

A prospective study revealing the role of an immune-related eRNA, WAKMAR2, in breast cancer.

Linbang Wang1, Jingkun Liu2, Jiaojiao Tai2, Nian Zhou1, Tianji Huang1, Yuzhou Xue3, Zhengxue Quan4.   

Abstract

Enhancer RNAs (eRNAs) are a subclass of non-coding RNAs that are generated during the transcription of enhancer regions and play an important role in tumourigenesis. In this study, we focused on the crucial eRNAs that participate in immune responses in invasive breast cancer (IBC). We first used The Cancer Genome Atlas and Human enhancer RNA Atlas to screen for tissue-specific eRNAs and their target genes. Through Pearson correlation analysis with immune genes, the eRNA WAKMAR2 was identified as a key candidate involved in IBC. Our further research suggested that WAKMAR2 is crucial in regulating the tumour microenvironment and may function by regulating immune-related genes, including IL27RA, RAC2, FABP7, IGLV1-51, IGHA1, and IGHD. Quantitative reverse transcription-polymerase chain reaction was used to detect the expression of WAKMAR2 in IBC and normal tissues, and the effect of WAKMAR2 on the regulation of downstream genes in MB-231 and MCF7 cells was studied in vitro. WAKMAR2 was found to be highly involved in tumour immunity and was downregulated in IBC tissues. Furthermore, the expression of WAKMAR2 and its target genes was observed at the pan-cancer level. This study provides evidence to suggest new potential targets for the treatment of breast cancer.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34321580     DOI: 10.1038/s41598-021-94784-3

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  32 in total

Review 1.  Cancer immunology--analysis of host and tumor factors for personalized medicine.

Authors:  Shuji Ogino; Jérôme Galon; Charles S Fuchs; Glenn Dranoff
Journal:  Nat Rev Clin Oncol       Date:  2011-08-09       Impact factor: 66.675

Review 2.  Enhancers as non-coding RNA transcription units: recent insights and future perspectives.

Authors:  Wenbo Li; Dimple Notani; Michael G Rosenfeld
Journal:  Nat Rev Genet       Date:  2016-03-07       Impact factor: 53.242

3.  Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential.

Authors:  Joo-Hyung Lee; Feng Xiong; Wenbo Li
Journal:  RNA Biol       Date:  2020-01-19       Impact factor: 4.652

Review 4.  Overcoming Endocrine Resistance in Breast Cancer.

Authors:  Ariella B Hanker; Dhivya R Sudhan; Carlos L Arteaga
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

5.  A High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer.

Authors:  Han Chen; Han Liang
Journal:  Cancer Cell       Date:  2020-10-01       Impact factor: 31.743

Review 6.  Enhancers: five essential questions.

Authors:  Len A Pennacchio; Wendy Bickmore; Ann Dean; Marcelo A Nobrega; Gill Bejerano
Journal:  Nat Rev Genet       Date:  2013-04       Impact factor: 53.242

Review 7.  Tissue-resident memory T cells in breast cancer control and immunotherapy responses.

Authors:  Ann Byrne; Peter Savas; Sneha Sant; Ran Li; Balaji Virassamy; Stephen J Luen; Paul A Beavis; Laura K Mackay; Paul J Neeson; Sherene Loi
Journal:  Nat Rev Clin Oncol       Date:  2020-02-28       Impact factor: 66.675

Review 8.  Progress in adjuvant systemic therapy for breast cancer.

Authors:  Noam F Pondé; Dimitrios Zardavas; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2019-01       Impact factor: 66.675

9.  Bioinformatic profiling of prognosis-related genes in the breast cancer immune microenvironment.

Authors:  Fang Bai; Yuchun Jin; Peng Zhang; Hongliang Chen; Yipeng Fu; Mingdi Zhang; Ziyi Weng; Kejin Wu
Journal:  Aging (Albany NY)       Date:  2019-11-12       Impact factor: 5.682

Review 10.  Personalized early detection and prevention of breast cancer: ENVISION consensus statement.

Authors:  Nora Pashayan; Antonis C Antoniou; Urska Ivanus; Laura J Esserman; Douglas F Easton; David French; Gaby Sroczynski; Per Hall; Jack Cuzick; D Gareth Evans; Jacques Simard; Montserrat Garcia-Closas; Rita Schmutzler; Odette Wegwarth; Paul Pharoah; Sowmiya Moorthie; Sandrine De Montgolfier; Camille Baron; Zdenko Herceg; Clare Turnbull; Corinne Balleyguier; Paolo Giorgi Rossi; Jelle Wesseling; David Ritchie; Marc Tischkowitz; Mireille Broeders; Dan Reisel; Andres Metspalu; Thomas Callender; Harry de Koning; Peter Devilee; Suzette Delaloge; Marjanka K Schmidt; Martin Widschwendter
Journal:  Nat Rev Clin Oncol       Date:  2020-06-18       Impact factor: 65.011

View more
  3 in total

Review 1.  Enhancer RNAs (eRNAs) in Cancer: The Jacks of All Trades.

Authors:  Sara Napoli; Nicolas Munz; Francesca Guidetti; Francesco Bertoni
Journal:  Cancers (Basel)       Date:  2022-04-14       Impact factor: 6.575

Review 2.  Inflammatory Immune-Associated eRNA: Mechanisms, Functions and Therapeutic Prospects.

Authors:  Lilin Wan; Wenchao Li; Yuan Meng; Yue Hou; Ming Chen; Bin Xu
Journal:  Front Immunol       Date:  2022-04-19       Impact factor: 8.786

Review 3.  Enhancer RNA (eRNA) in Human Diseases.

Authors:  Yunzhe Wang; Chenyang Zhang; Yuxiang Wang; Xiuping Liu; Zhao Zhang
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.